Project Grant R01AI201538
Award Date 8/17/26
Completion Date 7/31/31
Dollars Obligated $850K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital of Philadelphia $906,255 on July 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to discover and characterize novel genes regulating follicular helper T cell function in antibody responses. The research combines variant-to-gene mapping approaches in human follicular helper T cells to identify disease-associated genetic variation influencing B cell antibody responses. Aim...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $489,500 to The Children's Hospital of Philadelphia Research Institute on June 11, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This two-year project, which extends through May 31, 2027, focuses on developing novel sequencing methodologies and analytical pipelines to identify and characterize intact human immunodeficiency virus (HIV) reservoir cells...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital of Philadelphia $670,017 on February 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define a regulatory pathway in type 2 innate lymphoid cells that prevents chronic allergic lung inflammation and airways hyperresponsiveness. The award funds research into the E3 ubiquitin ligase CUL5 and its role in restricting cytokine receptor signaling in ILC2s. Preliminary data...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital of Philadelphia $853,112 on February 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of pilus-associated proteins PILC1 and PILC2 in Kingella kingae pathogenicity. Kingella kingae is an invasive gram-negative pathogen causing up to 88 percent of bone and joint infections in young children. Performance occurs in Philadelphia, Pennsylvania, from the...
- The National Institute of Allergy and Infectious Diseases awarded the Children's Hospital of Philadelphia $889,516 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct the Antibiotic Drug Exposures and Endotracheal Pharmacokinetics (DEEP) study. The research aims to understand factors governing antibiotic delivery to the lower respiratory tract in critically ill children, examine how antibiotic concentrations relate to changes in the...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Children's Hospital of Philadelphia Research Institute a Project Grant totaling $3,375,359 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 9, 2025. The four-year research initiative, with anticipated completion by June 30, 2029, will deliver scientific research focused on understanding the mechanisms of epithelial reprogramming and barrier dysfunction in...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $267,000 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research decoding gasdermin D (GSDMD) pore clustering as a regulatory checkpoint controlling pyroptosis, a lytic and inflammatory form...
- The National Institute of Allergy and Infectious Diseases (NIAID), within the Department of Health and Human Services National Institutes of Health, awarded $165,456 to The Children's Hospital of Philadelphia Research Institute on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant K08AI203036). The award funds research examining how influenza A virus and hydroxychloroquine shape the presentation of self-antigens in systemic lupus erythematosus...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $762,086 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify signaling networks that contribute to TH17-mediated neuroinflammation in multiple sclerosis. The recipient will develop a comprehensive suite of mass spectrometry proteomics tools to characterize protein abundance and phosphorylation in pathogenic TH17 cells at the systems level using the...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital of Philadelphia $448,292 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of ceftazidime-avibactam in combination with meropenem in the prevention and treatment of mutant KPC-producing infections using a hollow fiber infection model. KPC-producing Enterobacterales infections carry mortality rates upwards of 40 percent....